@article{article_217523, title={Sorafenib-induced pancreatitis}, journal={Journal of Experimental and Clinical Medicine}, volume={32}, pages={133–135}, year={2015}, author={Ayyıldız, Talat and Aydın, Taner and Eminler, Ahmet Tarık and Yıldırım, Çınar and Irak, Kader and Kıyıcı, Murat and Gürel, Selim and Nak, Selim Giray and Gülten, Macit and Dolar, Enver}, keywords={Hepatocellular carcinoma, Pancreatitis, Sorafenib, Tyrosine kinase inhibitor}, abstract={<table cellspacing="0" cellpadding="0"> <tbody> <tr> <td valign="top"> <p>Sorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis.  </p> </td> </tr> </tbody> </table>}, number={3}, publisher={Ondokuz Mayıs Üniversitesi} }